The main activity of our Startup is to produce, evaluate and valorize products originated from the marine world, and in particular from corals. These interesting products, totally new and unknown, are essentially protein-based. A strong collaboration with the researchers of the Centre Scientifique de Monaco (CSM) will allow us to identify and select the genes (DNA sequences) corresponding to the proteins of interest. In this particular context, it is worth emphasizing that the company will be defined as a “spin off” of the CSM.
From a practical point of view, our skills and knowledge, coupled with a specific biotechnological platform (currently housed at CSM), allow the production, the purification and the quality control of specific coral products. Moreover, we are able to generate levels of production up to pilot scale (pre-industrial). We then provide sufficient quantity of product to allow their biological evaluation by Contract Research Organizations (CROs). By this mean, we wi...
The main activity of our Startup is to produce, evaluate and valorize products originated from the marine world, and in particular from corals. These interesting products, totally new and unknown, are essentially protein-based. A strong collaboration with the researchers of the Centre Scientifique de Monaco (CSM) will allow us to identify and select the genes (DNA sequences) corresponding to the proteins of interest. In this particular context, it is worth emphasizing that the company will be defined as a “spin off” of the CSM.
From a practical point of view, our skills and knowledge, coupled with a specific biotechnological platform (currently housed at CSM), allow the production, the purification and the quality control of specific coral products. Moreover, we are able to generate levels of production up to pilot scale (pre-industrial). We then provide sufficient quantity of product to allow their biological evaluation by Contract Research Organizations (CROs). By this mean, we wish to determine the potential cosmetic, pharmaceutical and / or medical properties of our products. The most significant biological effects will be valorized through patent filings. The “B2B”-type commercial activity aims to negotiate exclusive licenses with companies interested by our products. We will also be able to offer a billed service of production to customers that wish performing biological evaluation according to their own specifications.
Our first product, originating from red coral, is currently the subject of a patent application for its skin protection properties. It is of great interest for an international cosmetic group with whom we have entered into negotiations for the establishment of an exclusive license agreement for a future commercial exploitation.
We also have a large panel of other potential candidates that are part of our "drug pipeline". These represent an asset to boost the further development of the company.
Finally, an R&D activity will be developed to maintain our ability to innovate through projects with high potential of valorization. As a first project, we will aim to optimize the production yields of coral proteins and potentially any other recombinant protein. Second, we want to investigate future genetic manipulation of corals for research and production purposes.
More information